Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease
Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, and professor of medicine for the Division of Liver Disease, Icahn School of Medicine at Mount Sinai joins eHealth Radio and the Health News and Technology Channels to discuss noninvasive liver screening to halt the progression of liver disease.
Listen to interview with host Eric Michaels and guest Dr. Douglas Dieterich discuss the following:
Please share with us the importance of ongoing assessment of liver stiffness and fat as part of a liver health assessment?
What role does FibroScan play in the diagnoses of chronic liver diseases and cirrhosis?
What is the risk of hepatocellular carcinoma (HCC) in people with long-term liver diseases, and if the liver is scarred by infection with hepatitis B or hepatitis C?
Tell us more about the use of FibroScan in hospital settings to improve outcomes and reduce costs in the assessment of liver disease.
Where do you see this going in terms of management and improving outcomes?
Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.
He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.
Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.
Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.
Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.
Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.